The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC).

被引：1
|
作者：
Hadji, P.
Ziller, M.
Maurer, T.
Muth, M.
Ruebel, A.
May, C.
Birkholz, K.
Gschwend, J. E.
机构：
[1] Univ Marburg, Marburg, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Dept Urol, D-80290 Munich, Germany
[3] Novartis Pharma GmbH, Nurnberg, Germany
[4] Novartis GmbH, Nurnberg, Germany
[5] Novartis Pharmaceut, Nurnberg, Germany
[6] Tech Univ Munich, D-80290 Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4614
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4614
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy of Combined Androgen Blockade with Zoledronic Acid Treatment in Prostate Cancer with Bone Metastasis: The ZABTON-PC (Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer) Study
    Ueno, Satoru
    Mizokami, Atsushi
    Fukagai, Takashi
    Fujimoto, Naohiro
    Oh-Oka, Hitoshi
    Kondo, Yukihiro
    Arai, Gaku
    Ide, Hisamitsu
    Horie, Shigeo
    Ueki, Osamu
    Kawaguchi, Kouhei
    Shimamura, Masayoshi
    Orito, Matsuo
    Ishida, Takeyuki
    Ikeda, Daisuke
    Namiki, Mikio
    ANTICANCER RESEARCH, 2013, 33 (09) : 3837 - 3844
  • [42] Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: The Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer (Zabton-PC) study
    Ueno, Satoru
    Mizokami, Atsushi
    Fukagai, Takashi
    Fujimoto, Naohiro
    Ohoka, Hitoshi
    Kondo, Yukihiro
    Arai, Gaku
    Ide, Hisamitsu
    Namiki, Mikio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [43] The effect of zoledronic acid on bone mineral density and bone turnover in patients with early breast cancer on the AZURE trial
    Shankland, C.
    Coleman, R.
    BREAST, 2011, 20 : S71 - S71
  • [44] Breast cancer bone metastases: denosumab or zoledronic acid?
    Gabri van der Pluijm
    Nature Reviews Endocrinology, 2011, 7 : 134 - 135
  • [45] Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid
    Yanaea, Masashi
    Fujimoto, Shinichiro
    Tane, Kaori
    Tanioka, Maki
    Fujiwara, Kimiko
    Tsubaki, Masanobu
    Yamazoe, Yuzuru
    Morishima, Yoshiyuki
    Chiba, Yasutaka
    Takao, Shintaro
    Komoike, Yoshifumi
    Tsurutani, Junji
    Nakagawa, Kazuhiko
    Nishida, Shozo
    JOURNAL OF BONE ONCOLOGY, 2017, 8 : 18 - 22
  • [46] Zoledronic acid (zol) provides long-term palliation of bone pain in breast cancer (bc) patients (pts) with bone metastases
    Lothman, H.
    Heatley, S.
    Lipton, A.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2006, 10 (03) : 225 - 226
  • [47] A Comparative Study of Intravenous Ibandronate and Pamindronate in Patients With Bone Metastases From Breast or Lung Cancer: Effect on Metastatic Bone Pain
    Heras, Panagiotis
    Hatzopoulos, Antonios
    Heras, Vasilios
    Kritikos, Nikolaos
    Karagiannis, Stefanos
    Kritikos, Konstantinos
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (05) : 340 - 342
  • [48] Effect of zoledronic acid (Zol) compared with pamidronate (Pam) on disease progression in breast cancer (BC) patients with bone metastases stratified by baseline characteristics.
    Hei, Y.
    Lipton, A.
    Shirina, N.
    Chen, Y. M.
    Xie, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 47S - 47S
  • [49] Effect of zoledronic acid on bone loss associated with androgen blockade for prostate cancer
    Casey, R
    Love, W
    Pearson, D
    Reymond, D
    Zarenda, M
    BONE, 2004, 34 : S84 - S84
  • [50] IMPACT OF ZOLEDRONIC ACID ON FRACTURES AND MORTALITY IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES
    Henk, H. J.
    Kaura, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 284 - 285
12345